162 related articles for article (PubMed ID: 31580153)
1. Ferric carboxymaltose for patients with heart failure and iron deficiency in Italy: cost-effectiveness and budget impact.
Rognoni C; Gerzeli S
J Comp Eff Res; 2019 Oct; 8(13):1099-1110. PubMed ID: 31580153
[No Abstract] [Full Text] [Related]
2. Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France.
Bourguignon S; Faller M; Champs FO; Moutier H; Levesque K; Caranhac G; Cohen-Solal A
ESC Heart Fail; 2019 Jun; 6(3):559-569. PubMed ID: 31021531
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of ferric carboxymaltose in iron-deficient patients with chronic heart failure in Sweden.
Hofmarcher T; Borg S
J Med Econ; 2015; 18(7):492-501. PubMed ID: 25766863
[TBL] [Abstract][Full Text] [Related]
4. Budget impact of parenteral iron treatment of iron deficiency: methodological issues raised by using real-life data.
Brock E; Braunhofer P; Troxler J; Schneider H
Eur J Health Econ; 2014 Dec; 15(9):907-16. PubMed ID: 24081613
[TBL] [Abstract][Full Text] [Related]
5. A Cost-effectiveness Analysis of Ferric Carboxymaltose in Patients With Iron Deficiency and Chronic Heart Failure in Spain.
Comín-Colet J; Rubio-Rodríguez D; Rubio-Terrés C; Enjuanes-Grau C; Gutzwiller FS; Anker SD; Ponikowski P
Rev Esp Cardiol (Engl Ed); 2015 Oct; 68(10):846-51. PubMed ID: 25649970
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and cost effectiveness of intravenous ferric carboxymaltose versus iron sucrose in adult patients with iron deficiency anaemia.
Basha A; Ibrahim MIM; Hamad A; Chandra P; Omar NE; Abdullah MAJ; Aldapt MB; Hussein RM; Mahfouz A; Adel AA; Shwaylia HM; Ekeibed Y; AbuMousa R; Yassin MA
PLoS One; 2021; 16(8):e0255104. PubMed ID: 34375369
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of implementing ESC guidelines for treatment of iron deficiency in heart failure in the Nordic countries.
Hofmarcher T; Cabrales Alin D; Linde C
Scand Cardiovasc J; 2018 Dec; 52(6):348-355. PubMed ID: 30457358
[TBL] [Abstract][Full Text] [Related]
8. A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom.
Pollock RF; Muduma G
J Med Econ; 2020 Jul; 23(7):751-759. PubMed ID: 32208038
[No Abstract] [Full Text] [Related]
9. An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
Pollock RF; Muduma G
Adv Ther; 2018 Dec; 35(12):2128-2137. PubMed ID: 30456520
[TBL] [Abstract][Full Text] [Related]
10. Economic Evaluation of Ferric Carboxymaltose for the Management of Hemodialysis Patients with Iron Deficiency Anemia in Italy.
Rognoni C; Ortalda V; Biasi C; Gambaro G
Adv Ther; 2019 Nov; 36(11):3253-3264. PubMed ID: 31489572
[TBL] [Abstract][Full Text] [Related]
11. Effects of a multifaceted intervention to promote the use of intravenous iron sucrose complex instead of ferric carboxymaltose in patients admitted for more than 24 h.
Touchard J; Perrin G; Berdot S; Pouchot J; Loustalot MC; Sabatier B
Eur J Clin Pharmacol; 2021 Feb; 77(2):189-195. PubMed ID: 32926203
[TBL] [Abstract][Full Text] [Related]
12. Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UK.
Gutzwiller FS; Schwenkglenks M; Blank PR; Braunhofer PG; Mori C; Szucs TD; Ponikowski P; Anker SD
Eur J Heart Fail; 2012 Jul; 14(7):782-90. PubMed ID: 22689292
[TBL] [Abstract][Full Text] [Related]
13. The health care cost of intravenous iron treatment in IBD patients depends on the economic evaluation perspective.
Bager P; Dahlerup JF
J Crohns Colitis; 2010 Oct; 4(4):427-30. PubMed ID: 21122539
[TBL] [Abstract][Full Text] [Related]
14. Impact of ferric carboxymaltose for iron deficiency at discharge after heart failure hospitalization: a European multinational economic evaluation.
McEwan P; Harrison C; Binnie R; Lewis RD; Cohen-Solal A; Lund LH; Ohlsson M; von Haehling S; Comin-Colet J; Pascual-Figal DA; Wächter S; Dorigotti F; de Arellano AR; Ponikowski P; Jankowska EA
Eur J Heart Fail; 2023 Mar; 25(3):389-398. PubMed ID: 36718652
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of cost savings with ferric carboxymaltose in anemia treatment through its impact on erythropoiesis-stimulating agents and blood transfusion: French healthcare payer perspective.
Luporsi E; Mahi L; Morre C; Wernli J; de Pouvourville G; Bugat R
J Med Econ; 2012; 15(2):225-32. PubMed ID: 22077267
[TBL] [Abstract][Full Text] [Related]
16. Financial impact of intravenous iron treatments on the management of anaemia inpatients: a 1 year observational study.
Delpeuch A; Ruivard M; Abergel A; Aumaitre O; Boisgard S; Bagel S; Sautou V
Int J Clin Pharm; 2018 Jun; 40(3):686-692. PubMed ID: 29520555
[TBL] [Abstract][Full Text] [Related]
17. Budget Impact Analysis of Oral Fisiogen Ferro Forte
Darbà J; Ascanio M
Clin Drug Investig; 2018 Sep; 38(9):801-811. PubMed ID: 29934762
[TBL] [Abstract][Full Text] [Related]
18. Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost-effectiveness analysis utilising AFFIRM-AHF.
McEwan P; Ponikowski P; Davis JA; Rosano G; Coats AJS; Dorigotti F; O'Sullivan D; Ramirez de Arellano A; Jankowska EA
Eur J Heart Fail; 2021 Oct; 23(10):1687-1697. PubMed ID: 34191394
[TBL] [Abstract][Full Text] [Related]
19. [Economic impact of ferric carboxymaltose in haemodialysis patients].
Aiello A; Berto P; Conti P; Panichi V; Rosati A
G Ital Nefrol; 2020 Aug; 37(Suppl 75):. PubMed ID: 32749086
[TBL] [Abstract][Full Text] [Related]
20. Budget impact of ferric carboxymaltose treatment in patients with chronic heart failure and iron deficiency in Spain.
Delgado JF; Oliva J; González-Franco Á; Cepeda JM; García-García JÁ; González-Domínguez A; Garcia-Casanovas A; Jiménez Merino S; Comín-Colet J
J Med Econ; 2020 Dec; 23(12):1418-1424. PubMed ID: 33073660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
